Trially AI Company Profile

Background

Trially AI is a Kansas City-based health technology startup founded in September 2023 by Kyle McAllister, Ramon Prieto, and Trevor Welch. The company aims to revolutionize the clinical trial recruitment process by leveraging artificial intelligence (AI) to match patients with appropriate clinical trials efficiently.

Key Strategic Focus

Trially's strategic focus centers on:

AI-Driven Patient Matching: Utilizing AI to analyze electronic health records (EHRs) and identify suitable candidates for clinical trials, thereby accelerating patient enrollment and reducing recruitment timelines.

Integration with Existing Systems: Ensuring seamless integration with various EHR, CRM, and CTMS platforms to maintain existing workflows and enhance operational efficiency.

Enhancing Clinical Trial Efficiency: Addressing the bottlenecks in patient recruitment to expedite the delivery of life-saving therapies to market.

Financials and Funding

In early 2024, Trially secured early-stage venture capital funding from investors including Alpaca VC and Redbud VC. The company also participated in Digital Sandbox KC’s program, receiving mentorship and up to $20,000 in funding to advance its platform.

Technological Platform and Innovation

Trially's platform stands out due to:

Proprietary AI Technology: A HIPAA-compliant AI system that analyzes unstructured EHR data, including physician notes, demographics, diagnoses, medications, imaging, labs, and pathology, to identify eligible patients for clinical trials.

Rapid Protocol Processing: The platform can process multiple clinical trial protocols and generate filter-friendly study criteria cards within minutes, significantly reducing manual chart review time.

Seamless Integration: Designed to integrate with any EHR, CRM, or CTMS system, maintaining existing workflows and ensuring data security and compliance with HIPAA, SOC 2, and FDA Part 11 regulations.

Leadership Team

Kyle McAllister, CEO & Co-founder: An industry veteran with extensive experience in healthcare IT, including roles at Cerner Corp. and Aetna. He has a track record of successful entrepreneurial ventures.

Ramon Prieto, CTO & Co-founder: A senior AI/ML engineer who re-architected Zapier's data infrastructure.

Trevor Welch, CPO & Co-founder: Former Head of Data Products at Zapier, specializing in AI and natural language processing, with prior entrepreneurial successes.

Competitor Profile

Market Insights and Dynamics

The U.S. clinical trial industry was valued at $22.6 billion in 2021, with a global valuation of $80.7 billion in 2023. The industry faces challenges in patient recruitment, leading to delays and increased costs in drug development.

Competitor Analysis

Key competitors in the AI-driven clinical trial recruitment space include:

Trials.ai: Focuses on optimizing clinical trial design and execution using AI to streamline processes and improve outcomes.

Hawthorne Effect: Provides remote clinical trial monitoring and data collection services to enhance trial efficiency.

TrialJectory: Utilizes AI to match cancer patients with clinical trials, aiming to democratize access to advanced treatments.

Deep 6 AI: Employs AI to analyze clinical data and identify eligible patients for trials, reducing recruitment time and costs.

Strategic Collaborations and Partnerships

Trially has established significant partnerships to enhance its platform's reach and effectiveness:

Athenahealth Marketplace Integration: In January 2025, Trially joined athenahealth’s Marketplace program, making its AI matching software available to over 160,000 healthcare providers. This integration aims to streamline patient enrollment in clinical trials with unprecedented speed and precision.

Collaboration with Hart Inc.: Trially is working with Hart Inc., a health IT company specializing in EHR data, to bring its product to market more effectively.

Operational Insights

Trially's AI platform has demonstrated significant improvements in clinical trial recruitment:

Increased Enrollment: Achieved a twofold increase in monthly patient enrollment for complex weight loss studies.

Reduced Screen Failure Rates: Decreased screen failure rates by 60%, from 52% to 20%.

Time Efficiency: Reduced manual chart review hours by over 90%, from 36 to 2.5 hours monthly.

Rapid Candidate Identification: Pre-screened 500 trial-ready candidates within five minutes of protocol upload.

Strategic Opportunities and Future Directions

Trially aims to:

Expand Market Reach: Leverage partnerships like the one with athenahealth to broaden its user base among healthcare providers.

Enhance AI Capabilities: Continuously improve its AI algorithms to handle increasingly complex protocols and datasets.

Secure Additional Funding: Seek further investment to scale operations and accelerate product development.

Foster Industry Collaborations: Establish more partnerships with healthcare organizations and research institutions to enhance the platform's effectiveness and adoption.